Avalo Therapeutics's total assets for Q3 2025 were $125.10M, a decrease of -1.17% from the previous quarter. AVTX total liabilities were $33.55M for the fiscal quarter, a 52.45% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.